Taylors Acts for SoftBank Vision Fund Investment in Roivant Sciences

Taylors (in association with Walkers) has acted as Bermuda counsel to SoftBank Vision Fund, which led a $1.1 billion equity investment in Roivant Sciences. The investment, which includes existing shareholder participation, is intended to accelerate the launch of new subsidiaries within and beyond the biopharma industry. The Taylors team, led by partner Jonathan Betts, worked alongside Cooley LLP, as lead US counsel. 

“Roivant has attracted world-class talent in its pursuit of developing and commercializing drugs that target large unmet medical needs,” said Akshay Naheta, managing director of SoftBank Group International, in a news release. “We are impressed with the ambition and track record of the Roivant team and look forward to supporting them in the next step of their journey, as they look to effectively harness technology and leverage big data across all aspects of their business.”

Roivant, which was founded in 2014, is dedicated to transformative innovation in healthcare. It focuses on realizing the full potential of promising biomedical research by developing and commercializing novel therapies across diverse therapeutic areas. It partners with innovative biopharmaceutical companies and academic institutions to ensure that important medicines are rapidly developed and delivered to patients.

The SoftBank Vision Fund invests globally in the businesses and technologies that will enable the next stage of the Information Revolution, and make tomorrow’s world leading businesses possible. It invests across all technology sectors and geographies, including computational biology, data-driven healthcare and technology-enabled pharmaceutical businesses.

Jonathan BettsPartner - TaylorsT +1 441 242 1511jonathan.betts@walkersglobal.com